Silence Therapeutics plc
SLN
$7.35
$0.456.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 559.00K | 25.83M | 27.17M | 27.70M | 43.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 559.00K | 25.83M | 27.17M | 27.70M | 43.26M |
| Cost of Revenue | 215.00K | 2.24M | 5.82M | 9.06M | 11.81M |
| Gross Profit | 344.00K | 23.59M | 21.35M | 18.64M | 31.45M |
| SG&A Expenses | 22.34M | 24.15M | 26.05M | 27.93M | 26.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.85M | 95.82M | 99.01M | 99.93M | 92.84M |
| Operating Income | -82.29M | -69.99M | -71.84M | -72.23M | -49.58M |
| Income Before Tax | -88.60M | -64.21M | -78.74M | -70.93M | -44.46M |
| Income Tax Expenses | 11.00K | 335.00K | 383.00K | 601.00K | 845.00K |
| Earnings from Continuing Operations | -88.61 | -64.54 | -79.13 | -71.53 | -45.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.61M | -64.54M | -79.13M | -71.53M | -45.31M |
| EBIT | -82.29M | -69.99M | -71.84M | -72.23M | -49.58M |
| EBITDA | -81.74M | -69.41M | -71.26M | -71.65M | -48.99M |
| EPS Basic | -5.63 | -4.10 | -5.03 | -4.56 | -2.91 |
| Normalized Basic EPS | -1.15 | -0.83 | -1.03 | -0.94 | -0.59 |
| EPS Diluted | -5.63 | -4.10 | -5.03 | -4.56 | -2.91 |
| Normalized Diluted EPS | -1.15 | -0.83 | -1.03 | -0.94 | -0.59 |
| Average Basic Shares Outstanding | 188.93M | 188.92M | 188.75M | 188.26M | 184.99M |
| Average Diluted Shares Outstanding | 62.98M | 62.97M | 62.92M | 62.75M | 61.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |